

1 ***Prevalence of Elevated Blood Pressure and Left Ventricular Hypertrophy in Adolescents with***  
2 ***Congenital Heart Disease***

3 Aaron T. Walsh<sup>1,4</sup>, MD; Kan N. Hor, MD<sup>1,4\*</sup>; Mariah Eisner, MS<sup>1,2</sup>; Mahmoud Kallash, MD<sup>3,4</sup>; John  
4 David Spencer, MD<sup>3,4</sup>; Andrew H. Tran, MD, MS<sup>1,4\*</sup>

5 \* Equal contribution

6 <sup>1</sup>The Heart Center, Nationwide Children's Hospital, Columbus, OH

7 <sup>2</sup>Biostatistics Resource at Nationwide Children's Hospital, Columbus, OH

8 <sup>3</sup>Division of Nephrology and Hypertension, Nationwide Children's Hospital, Columbus, OH

9 <sup>4</sup>Department of Pediatrics, The Ohio State University, Columbus, OH

10

11 Prevalence of HTN and LVH in Adolescents with CHD

12

13 Corresponding author:

14 Andrew H. Tran, MD, MS

15 The Heart Center, Nationwide Children's Hospital, Tower Building, Suite T4147,

16 700 Children's Drive, Columbus, OH 43205, USA. Tel.: +1-614-722-0630; Fax: +1, 614-722-2549;

17 [andrew.tran@nationwidechildrens.org](mailto:andrew.tran@nationwidechildrens.org)

18 Total Word Count: 5,211

19 **Abstract**

20 **Background:** Left ventricular hypertrophy (LVH) associated with hypertension (HTN) is a  
21 predictor of cardiovascular (CV) events in adulthood. LVH is defined using left ventricular mass  
22 indexed to height<sup>2.7</sup> (LVMI-ht<sup>2.7</sup>) with current guidelines using the adult cutoff of 51 g/ht<sup>2.7</sup>;  
23 however, the pediatric cutoff is lower. Adults with congenital heart disease (CHD) have higher  
24 rates of HTN compared to the general adult population. Data on the prevalence of elevated  
25 blood pressure (SBP) in youths with CHD is limited. The aim of our study was to determine the  
26 prevalence of elevated BP and LVH in adolescents with CHD.

27 **Methods:** We retrospectively analyzed echocardiograms from patients with CHD from 2012-  
28 2019. Patients with biventricular CHD aged 13-17 years with documented BP, height, weight,  
29 and measurement of LVMI-ht<sup>2.7</sup> were included. We defined LVH using the pediatric cutoff of  
30 LVMI-ht<sup>2.7</sup>  $\geq$  38.6 g/ht<sup>2.7</sup>. Patients were grouped by BP category into normotensive (NT, SBP <  
31 120 mm Hg), Elevated BP (E-BP, 120  $\leq$  SBP < 130 mm Hg), Stage 1 HTN (HTN-1, 130  $\leq$  SBP < 140  
32 mm Hg), and Stage 2 HTN (HTN-2, SBP  $\geq$  140 mm Hg). Prevalence of LVH was reported in each  
33 group defined as LVMI-HT<sup>2.7</sup>  $\geq$  38.6 g/ht<sup>2.7</sup>.

34 **Results:** 855 patients were included. Mean ( $\pm$  standard deviation, SD) age was 15.5 $\pm$ 1.5 years  
35 with 485/855 (56.7%) male, SBP 117 $\pm$ 13.5 mmHg, and LVMI-ht<sup>2.7</sup> 34.2 $\pm$ 10.5 g/ht<sup>2.7</sup>. 493/855  
36 (57.7%) were in the NT group, 214/855 (25%) in E-BP, 99/855 (11.6%) in HTN-1, and 49/855  
37 (5.7%) in HTN-2. Prevalence of LVH increased with higher SBP with 96/493  
38 (19.5%) in NT, 80/214 (37.4%) in E-BP, 32/99 (32.3%) in HTN-1, and 20/49 (40.8%) in HTN-

39 2. Of youths with LVH, 49/228 (21.5%) met adult criteria of  $\geq 51 \text{ g/ht}^{2.7}$ . Age, male sex, and body  
40 mass index (BMI) percentile were significantly associated with increased LVMI-ht<sup>2.7</sup>.

41 **Conclusions:** Youths with CHD have a high prevalence of elevated BP, HTN, and LVH. BMI is a  
42 significant risk factor for the development of LVH in this population. These findings support  
43 early screening for HTN in this group because youths with CHD have baseline increased CV risk  
44 that may be compounded by obesity and long-term HTN.

#### 45 Clinical Perspective

- 46 • What is new?
  - 47 ○ The prevalence of abnormal blood pressure and LVH in adolescents with CHD is
  - 48 understudied and our data show that HTN and LVH are common in this
  - 49 population.
  - 50 ○ One-fifth of adolescents with biventricular congenital heart disease and left
  - 51 ventricular hypertrophy met adult criteria for left ventricular hypertrophy.
- 52 • What are the clinical implications?
  - 53 ○ Left ventricular hypertrophy secondary to hypertension is linked to adverse
  - 54 cardiac events in adulthood.
  - 55 ○ Early screening and detection for abnormal blood pressure in the adolescent
  - 56 congenital heart disease population may lead to earlier initiation of lifestyle
  - 57 interventions or pharmacotherapy and mitigate long-term adverse clinical and
  - 58 financial outcomes in an already vulnerable population.

59

60 **Introduction**

61 The global prevalence of congenital heart disease (CHD) is estimated to be 1.8 cases per 100  
62 live births<sup>1</sup> and accounts for one-third of all congenital anomalies<sup>2</sup>. With improvements in  
63 prenatal detection, postnatal care, pharmacologic agents, interventional techniques, and  
64 surgical outcomes, more patients born with CHD are living past the first decade of life. Adults  
65 with CHD now comprise two-thirds of the total CHD population<sup>3</sup> and manifest several  
66 cardiovascular (CV) risk factors at rates higher than the general adult population, including  
67 systolic hypertension (HTN)<sup>4</sup>.

68  
69 Left ventricular hypertrophy (LVH) as detected by echocardiography has long been associated  
70 with HTN and confers an increased risk of adverse CV events in adulthood. The Framingham  
71 Heart Study demonstrated that increased left ventricular mass (LVM) in adults was  
72 independently associated with CV disease, death from CV disease, and all-cause mortality even  
73 after adjustment for traditional risk factors<sup>5</sup>. The prognostic ability of LVH for CV events has  
74 held true across more diverse ethnic populations, the elderly, in those with essential HTN, and  
75 following myocardial infarction<sup>6-12</sup> with links to increased risk of stroke, heart failure, coronary  
76 artery disease, and arrhythmia<sup>6, 7, 12-14</sup>. In the general adolescent population with essential  
77 hypertension, a linear relationship was found between HTN and LVM<sup>15</sup>, with LVM values  
78 associated with a fourfold increase for CV disease in adulthood<sup>16</sup>. However, the prevalence of  
79 HTN and LVH in adolescents with CHD is less well-known. Therefore, the aim of our study was  
80 to determine the prevalence of HTN and LVH in this ever-growing population.

81

## 82 **Methods**

### 83 *Study Population*

84 We performed a retrospective analysis of an echocardiogram database and the  
85 Electronic Medical Record of adolescent patients aged 13-17 years with biventricular CHD  
86 (excluding those patients with single ventricular or functionally single ventricular lesions such as  
87 hypoplastic left heart syndrome, tricuspid atresia, and pulmonary atresia with intact ventricular  
88 septum, or others who have required single-ventricle palliation) from 2012-2019 at Nationwide  
89 Children's Hospital. We chose to study this age distribution as the blood pressure cutoffs in this  
90 population directly correlate with those in the adult population<sup>17</sup> in which adverse CV outcomes  
91 are described. Only patients with documented blood pressure, height, weight, body mass index  
92 (BMI), and echocardiographic data for LVM calculation at the time of their most recent  
93 echocardiogram were included.

94

### 95 *Echocardiogram Parameters and LVM*

96 For the purposes of this study, the echocardiographic measurements were measured off M-  
97 Mode, a standard for LV quantification in our lab during this timeframe. Demographic data and  
98 echocardiographic variables for assessment of LVH are included in **Table 1**. Measurements of  
99 the interventricular septum (IVSd) and left ventricular posterior wall (LVPWd) were taken at  
100 end-diastole. Left ventricular dimensions were taken at end-diastole (LVEDD) and end-systole  
101 (LVESD). LVM was determined via the formula proposed by Devereux et al:  $0.8 \times$   
102  $(1.04 \times [(IVS + LVID + PWT)^3 - LVID^3] + 0.6 \text{ grams})^{18}$ .

103 LVM was then indexed to body height to the power of 2.7 ( $LVM_{I-ht^{2.7}} = LVM / \text{height}^{2.7}$ ) to adjust  
104 for differences in body size<sup>18, 19</sup>. LV function was assessed by left ventricular shortening fraction  
105 (LVSF).

106

### 107 *Blood Pressure Definitions and Categories*

108 Patients were stratified by blood pressure category into normotensive (NT, SBP<120 mmHg),  
109 elevated blood pressure (E-BP, 120≤SBP<130 mmHg), stage 1 HTN (HTN-1, 130≤SBP<140  
110 mmHg), and stage 2 HTN (HTN-2, SBP≥140 mmHg) per the 2017 Clinical Practice Guideline  
111 (CPG) for Screening and Management of Blood Pressure in Children and Adolescents<sup>17</sup> utilizing  
112 the automated blood pressure taken at the time of their most recent echocardiogram. The  
113 prevalence of LVH was reported in each group using the pediatric cutoff for LVH of  $LVM_{I-ht^{2.7}} \geq$   
114  $38.6 \text{ g}/\text{ht}^{2.7}$  which corresponds to the 95th percentile for  $LVM_{I-ht^{2.7}}$  in children and increases  
115 the sensitivity for detecting LVH before it reaches a level associated with CV events in  
116 adulthood<sup>15, 20</sup>. Results were also compared to the 2017 CPG recommendation of  $LVM_{I-ht^{2.7}} \geq$   
117  $51\text{g}/\text{ht}^{2.7}$  for LVH, which is the adult cutoff associated with increased risk for cardiovascular  
118 events<sup>21</sup> but which is far above the 95<sup>th</sup> percentile values in pediatrics<sup>17</sup>.

119

### 120 *BMI stratification*

121 BMI percentiles were obtained from the Centers for Disease Control and Prevention growth  
122 charts. BMI z-scores were calculated by  $BMI_z = (BMI/M)L - 1 / (L * S)$ , where L, M, and S are  
123 reference values from the growth chart for the corresponding child age and sex. BMI  
124 percentiles were calculated from z-scores based on the normal distribution. Subjects were

125 categorized based on BMI percentile as normal weight (BMI < 85th percentile), overweight  
126 (85th percentile  $\leq$  BMI < 95th percentile), or obese (BMI  $\geq$  95th percentile).

127

### 128 *Statistical analysis*

129 Data were summarized using frequency (percentage) for categorical variables, mean (standard  
130 deviation, SD) for continuous symmetric variables, and median (interquartile range, IQR) for  
131 continuous skewed variables. Data were quality checked and distributions were visualized using  
132 bar and violin plots. For model stability, race groups were aggregated into white, black, or other  
133 (includes American Indian, Asian, Hispanic, Native American, Pacific Islander, biracial, and  
134 other). Prevalence of LVH among each blood pressure group was calculated. Among  
135 adolescents that met pediatric LVH criteria, the percentage also meeting the adult LVH criteria  
136 was calculated. Pairwise comparisons were performed for the echocardiogram parameters  
137 between each blood pressure category and adjusted for multiple comparisons utilizing the  
138 Bonferroni correction. Univariable linear regression models were constructed for continuous  
139 outcomes LVMI-ht<sup>2.7</sup>, LVEDD, LVESD, LVPWd, IVSd, LVSF, and LVEF. Predictor variables included  
140 age, sex, race, continuous SBP, and BMI percentile. Multivariable linear regression models were  
141 fit for each outcome with the same independent variables, using complete cases without  
142 missing predictors. The interaction term between SBP and BMI percentile was also assessed  
143 and removed from the model if not significantly associated with the outcome. P-values < 0.05  
144 were considered statistically significant. All statistical analyses were performed in R version 4.0  
145 (R Core Team, Vienna, Austria).

146

147 **Results**

148 *Patient Characteristics*

149 A total of 855 patients met the inclusion criteria (56.7% male) with mean (SD) age  $15.5 \pm 1.5$   
150 years (range 13.0 to 17.9 years). Patient characteristics can be found in **Table 1**. The race of  
151 patients was predominantly White (79.9%). BMI, BMI percentile, and body surface area (BSA)  
152 trended higher in the abnormal blood pressure groups. Over half of patients were NT (57.7%),  
153 with 25%, 11.6% and 5.7% meeting criteria for E-BP, HTN-1, and HTN-2, respectively.

154

155 *Echocardiogram Parameters*

156 Those in the E-BP and HTN-1 groups had higher LVEDD values compared to NT (**Table**  
157 **2**). Patients with abnormal BP had thicker LVPWd and IVSd compared to NT subjects. LVMI-ht<sup>2.7</sup>  
158 increased across blood pressure categories and was significantly higher in the abnormal blood  
159 pressure groups compared to NT. One-third of patients in the HTN-1 and 41% of patients in the  
160 HTN-2 category met criteria for LVH. Of the youths with LVH, one-fifth (21.5%) met the adult  
161 criteria for LVH with  $LVMI\text{-}ht^{2.7} \geq 51\text{g}/ht^{2.7}$ . Ejection fraction was preserved and consistent  
162 across blood pressure categories.

163

164 *Univariable and Multivariable Linear Regression Models*

165 Univariable linear regression demonstrated age, male sex, BMI percentile, and SBP were  
166 significantly associated with LVH (**Table 3**). After adjustment in a multivariable linear regression,  
167 age, male sex, and BMI percentile remained significant predictors of LVMI-ht<sup>2.7</sup> while SBP no  
168 longer correlated (**Table 4**). In a subgroup analysis of patients with normal BMI, SBP was an



169 independent predictor of LVMI-ht<sup>2,7</sup> ( $p=0.011$ ) on univariable analysis, but lost significance in  
170 the adjusted model.

171

## 172 **Discussion**

### 173 *HTN*

174 There is a paucity of data related to HTN and LVH in the adolescent congenital heart disease  
175 population. We found that in our large cohort of adolescents with biventricular CHD, over 40%  
176 had abnormal blood pressure. LVM was linearly associated with elevated blood pressure such  
177 that only 20% of those with normal blood pressure had LVH by echocardiography compared to  
178 35% of those with HTN. The rates of abnormal blood pressure in our group were higher than  
179 those previously reported for youth in the general population<sup>22-26</sup>, which may reflect the impact  
180 of the underlying CHD on vascular tone. Indeed, Mivelaz et al demonstrated elevated aortic  
181 stiffness in a similar cohort of adolescents with biventricular CHD<sup>27</sup>, which is a vascular marker  
182 linked to future cardiovascular morbidity and mortality<sup>28</sup>. This is not surprising given that  
183 patients with CHD often have several risk factors for HTN including chronic renal insufficiency as  
184 well as changes in arterial wall architecture that places them at higher risk of abnormal blood  
185 pressure<sup>29,30</sup>. High blood pressure did not remain a significant risk factor for LVH in  
186 multivariable regression analysis. We suspect this may be due to a longitudinal effect of blood  
187 pressure on LVM that may not be seen until the adult years. Nonetheless, we know that  
188 hypertensive youths are prone to becoming adults with HTN<sup>31-33</sup> and that identification of  
189 abnormal blood pressures in the formative years may play an important prognostic role.

190 Perhaps annual ambulatory blood pressure monitoring in adolescents with CHD would be best  
191 practice to screen for those already experiencing elevated blood pressures.

192

193 *LVH*

194 LVMI-ht<sup>2.7</sup> appeared to be higher in those with higher BP on univariate analysis consistent with  
195 previous findings in children and adolescents without CHD<sup>34</sup>. One-fifth of patients with LVH met  
196 adult criteria which is higher than levels previously reported for hypertensive young patients  
197 without CHD<sup>16</sup>, suggesting a compounding effect of underlying CHD on the development of  
198 LVH. Age, male sex, BMI percentile, and blood pressure were significantly associated with LVMI-  
199 ht<sup>2.7</sup> using univariable analysis. After adjusting for variables in a multilinear regression model,  
200 age, male sex, and BMI percentile remained significant predictors of LVMI-ht<sup>2.7</sup> while SBP lost  
201 its significance, similar to previous findings in adults by de Simone et al. <sup>18</sup>. However, data from  
202 the SHIP AHOY study group have demonstrated SBP to be a significant determinant of LVMI-  
203 ht<sup>2.7</sup> in healthy adolescents after adjusting for covariates<sup>15</sup>. Their cohort age range skewed older  
204 than the current data set, suggesting a longitudinal effect of SBP on LVMI-ht<sup>2.7</sup> which may have  
205 risen to significance on multivariate analysis in our cohort if given more time.

206

207 *BMI*

208 The association between obesity, HTN, and LVH in the general pediatric population is well-  
209 documented<sup>35-38</sup>. Children without CHD with overweight or obesity and HTN were found to  
210 have higher LVM indices at baseline and longitudinally compared to those of healthy weight  
211 who were hypertensive<sup>39</sup>. Our study of children with CHD mirrors these findings with one in five

212 patients having obesity and BMI percentile being significantly associated with LVMI-ht<sup>2,7</sup>. This is  
213 important because children with CHD can be at higher risk for future CV events compared to  
214 non-CHD children<sup>40</sup> so the presence of obesity and early echocardiographic changes may  
215 further compound future risk in these patients.

216

217 Weight continues to prove itself to be a crucial factor in the development of LVH. Similar to our  
218 findings, in a cohort of 160 pediatric patients from the Bogalusa Heart study, weight remained  
219 the only significant predictor for LVM in multivariate analysis after controlling for age, sex, and  
220 SBP<sup>41</sup>. Burke et al. found that adults in the MESA study who were obese had a two-fold  
221 increased risk of having LVM exceeding the 80<sup>th</sup> percentile compared to those with a normal  
222 body size after adjustment for traditional risk factors, making body size a potentially modifiable  
223 risk factor for subclinical CV disease<sup>42</sup>.

224

225 Our study was novel in having a large cohort of patients inclusive of a large spectrum of  
226 biventricular CHD. We also utilized the most up to date guidelines for characterizing HTN in the  
227 adolescent population<sup>17</sup> which is felt to capture more accurately those with abnormal blood  
228 pressures. Prior studies on HTN and LV geometry changes in CHD have focused primarily on  
229 coarctation of the aorta and its associated long-term outcomes<sup>43, 44</sup>. While our study included  
230 patients with left ventricular outflow tract (LVOT) obstructions, the majority of documented  
231 LVOT gradients on the echocardiograms used for this study demonstrated no or mild residual  
232 pressure gradient, indicating that a residual obstruction is less likely responsible for any  
233 observed increase in LVM. This study broadens our understanding of the impact of HTN and

234 overweight/obesity on children with CHD. Our study highlights the need for early detection of  
235 abnormal BP and obesity in patients with CHD to prevent progression of LVH to levels known to  
236 be associated with hard CV events. Knowledge of the risk for LVH in this age group becomes  
237 increasingly important considering findings that elevated LVM can be found at blood pressures  
238 below the current definition of pediatric HTN<sup>15</sup>. Furthermore, elevated blood pressure has  
239 been associated with systolic and diastolic dysfunction<sup>45, 46</sup> which may already be compromised  
240 by the patient's CHD. With the knowledge of early abnormal blood pressure and evidence of  
241 increased LVM in overweight and obese patients with CHD, it becomes vital to screen patients  
242 and to be vigilant about providing anticipatory guidance and considering pharmacological  
243 intervention in patients who meet criteria. This is especially important in light of evidence that  
244 regression in LVM leads to lesser risk of CV disease<sup>8</sup>. Targeted diet and lifestyle  
245 recommendations such as the Dietary Approaches to Stop Hypertension (DASH)<sup>17</sup> and the  
246 Cardiovascular Health Integrated Lifestyle Diet (CHILD) recommended by the American  
247 Academy of Pediatrics (AAP)<sup>47</sup> should be stressed particularly in this patient population.  
248 Physical activity recommendations should also be emphasized<sup>48</sup> depending on appropriate  
249 activity clearance by heart lesion. Current pediatric hypertension guidelines recommend yearly  
250 ambulatory blood pressure monitor (ABPM) placement in patients with repaired aortic  
251 coarctation<sup>17</sup>; however, ABPM can also be useful in screening other CHD patients for  
252 hypertension.

253

254 Limitations

255 While our study is one of the largest to evaluate BP and LVMI-ht<sup>2,7</sup> amongst the pediatric CHD  
256 population, there are several inherent limitations that should be noted. Our study is a single  
257 center retrospective cohort study which limits the ability to determine causation for increased  
258 LVM. We believe that with our large sample size, which encompasses all types of biventricular  
259 CHD, we avoided selection bias that can accompany some retrospective studies. To that end,  
260 we did not stratify by types of CHD and it is possible that our population potentially includes a  
261 larger percentage of patients with left ventricular outflow tract obstructive lesions which are  
262 known to be risk factors for LVH. This will need to be further elucidated in future studies. Given  
263 the descriptive nature of our work, whether patients were identified as hypertensive or if they  
264 were being actively treated for HTN was not investigated. Additionally, single time-point blood  
265 pressures were utilized for our analysis. Serial blood pressure evaluation and incorporation of  
266 ambulatory blood pressure monitoring data would further enhance our understanding of the  
267 true prevalence of HTN in this cohort and provide insight into the timing of development of  
268 end-organ damage. Future studies should be aimed at longitudinal changes in blood pressure  
269 and LVH and the impact of pharmacological intervention and social determinants on HTN,  
270 obesity, and evidence of cardiac dysfunction in the pediatric CHD population.

271

272

273 Acknowledgements

274 Sources of Funding: None

275 Disclosures: No authors have relevant disclosures.

276

277 **References**

- 278 1. Global, regional, and national burden of congenital heart disease, 1990-2017: A  
279 systematic analysis for the global burden of disease study 2017. *Lancet Child Adolesc*  
280 *Health*. 2020;4:185-200
- 281 2. van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, et al.  
282 Birth prevalence of congenital heart disease worldwide: A systematic review and meta-  
283 analysis. *J Am Coll Cardiol*. 2011;58:2241-2247
- 284 3. Marelli AJ, Ionescu-Iltu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime  
285 prevalence of congenital heart disease in the general population from 2000 to 2010.  
286 *Circulation*. 2014;130:749-756
- 287 4. Moons P, Van Deyk K, Dedroog D, Troost E, Budts W. Prevalence of cardiovascular risk  
288 factors in adults with congenital heart disease. *Eur J Cardiovasc Prev Rehabil*.  
289 2006;13:612-616
- 290 5. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of  
291 echocardiographically determined left ventricular mass in the framingham heart study.  
292 *N Engl J Med*. 1990;322:1561-1566
- 293 6. Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, et al. The relationship of left  
294 ventricular mass and geometry to incident cardiovascular events: The mesa (multi-  
295 ethnic study of atherosclerosis) study. *J Am Coll Cardiol*. 2008;52:2148-2155
- 296 7. Kawel-Boehm N, Kronmal R, Eng J, Folsom A, Burke G, Carr JJ, et al. Left ventricular mass  
297 at mri and long-term risk of cardiovascular events: The multi-ethnic study of  
298 atherosclerosis (mesa). *Radiology*. 2019;293:107-114
- 299 8. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic  
300 significance of serial changes in left ventricular mass in essential hypertension.  
301 *Circulation*. 1998;97:48-54
- 302 9. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous  
303 relation between left ventricular mass and cardiovascular risk in essential hypertension.  
304 *Hypertension*. 2000;35:580-586
- 305 10. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, et al. Left  
306 ventricular mass and cardiovascular morbidity in essential hypertension: The mavi  
307 study. *J Am Coll Cardiol*. 2001;38:1829-1835
- 308 11. Gardin JM, McClelland R, Kitzman D, Lima JA, Bommer W, Klopfenstein HS, et al. M-  
309 mode echocardiographic predictors of six- to seven-year incidence of coronary heart  
310 disease, stroke, congestive heart failure, and mortality in an elderly cohort (the  
311 cardiovascular health study). *Am J Cardiol*. 2001;87:1051-1057
- 312 12. Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, et al. Prognostic  
313 implications of left ventricular mass and geometry following myocardial infarction: The  
314 valiant (valsartan in acute myocardial infarction) echocardiographic study. *JACC*  
315 *Cardiovasc Imaging*. 2008;1:582-591
- 316 13. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, et al.  
317 Increased left ventricular mass is a risk factor for the development of a depressed left

- 318 ventricular ejection fraction within five years: The cardiovascular health study. *J Am Coll*  
319 *Cardiol.* 2004;43:2207-2215
- 320 14. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular  
321 arrhythmias in left ventricular hypertrophy: The framingham heart study. *Am J Cardiol.*  
322 1987;60:560-565
- 323 15. Urbina EM, Mendizabal B, Becker RC, Daniels SR, Falkner BE, Hamdani G, et al.  
324 Association of blood pressure level with left ventricular mass in adolescents.  
325 *Hypertension.* 2019;74:590-596
- 326 16. Daniels SR, Loggie JM, Houry P, Kimball TR. Left ventricular geometry and severe left  
327 ventricular hypertrophy in children and adolescents with essential hypertension.  
328 *Circulation.* 1998;97:1907-1911
- 329 17. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Clinical  
330 practice guideline for screening and management of high blood pressure in children and  
331 adolescents. *Pediatrics.* 2017;140
- 332 18. de Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH. Relation of obesity and  
333 gender to left ventricular hypertrophy in normotensive and hypertensive adults.  
334 *Hypertension.* 1994;23:600-606
- 335 19. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, et al. Left  
336 ventricular mass and body size in normotensive children and adults: Assessment of  
337 allometric relations and impact of overweight. *J Am Coll Cardiol.* 1992;20:1251-1260
- 338 20. Daniels SR, Kimball TR, Morrison JA, Houry P, Meyer RA. Indexing left ventricular mass  
339 to account for differences in body size in children and adolescents without  
340 cardiovascular disease. *Am J Cardiol.* 1995;76:699-701
- 341 21. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth  
342 on variability of left ventricular mass: Assessment of allometric signals in adults and  
343 children and their capacity to predict cardiovascular risk. *Journal of the American*  
344 *College of Cardiology.* 1995;25:1056-1062
- 345 22. McNiece KL, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ. Prevalence of  
346 hypertension and pre-hypertension among adolescents. *The Journal of Pediatrics.*  
347 2007;150:640-644.e641
- 348 23. Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and  
349 adolescents. *Jama.* 2007;298:874-879
- 350 24. Chioloro A, Cachat F, Burnier M, Paccaud F, Bovet P. Prevalence of hypertension in  
351 schoolchildren based on repeated measurements and association with overweight. *J*  
352 *Hypertens.* 2007;25:2209-2217
- 353 25. Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the  
354 prevalence of hypertension in school-aged children. *Pediatrics.* 2004;113:475-482
- 355 26. Moore WE, Stephens A, Wilson T, Wilson W, Eichner JE. Body mass index and blood  
356 pressure screening in a rural public school system: The healthy kids project. *Prev Chronic*  
357 *Dis.* 2006;3:A114-A114
- 358 27. Mivelaz Y, Leung MT, Zadorsky MT, De Souza AM, Potts JE, Sandor GG. Noninvasive  
359 assessment of vascular function in postoperative cardiovascular disease (coarctation of  
360 the aorta, tetralogy of fallot, and transposition of the great arteries). *Am J Cardiol.*  
361 2016;118:597-602



- 362 28. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-  
363 cause mortality with arterial stiffness: A systematic review and meta-analysis. *Journal of*  
364 *the American College of Cardiology*. 2010;55:1318-1327
- 365 29. Morgan CJ, Zappitelli M, Robertson CMT, Alton GY, Sauve RS, Joffe AR, et al. Risk factors  
366 for and outcomes of acute kidney injury in neonates undergoing complex cardiac  
367 surgery. *The Journal of Pediatrics*. 2013;162:120-127.e121
- 368 30. Roche SL, Silversides CK. Hypertension, obesity, and coronary artery disease in the  
369 survivors of congenital heart disease. *Can J Cardiol*. 2013;29:841-848
- 370 31. Tirosh A, Afek A, Rudich A, Percik R, Gordon B, Ayalon N, et al. Progression of  
371 normotensive adolescents to hypertensive adults: A study of 26,980 teenagers.  
372 *Hypertension*. 2010;56:203-209
- 373 32. Sun SS, Grave GD, Siervogel RM, Pickoff AA, Arslanian SS, Daniels SR. Systolic blood  
374 pressure in childhood predicts hypertension and metabolic syndrome later in life.  
375 *Pediatrics*. 2007;119:237-246
- 376 33. Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by  
377 tracking of elevated blood pressure from childhood to adulthood: The bogalusa heart  
378 study. *Am J Hypertens*. 1995;8:657-665
- 379 34. Stabouli S, Kotsis V, Rizos Z, Toumanidis S, Karagianni C, Constantopoulos A, et al. Left  
380 ventricular mass in normotensive, prehypertensive and hypertensive children and  
381 adolescents. *Pediatr Nephrol*. 2009;24:1545-1551
- 382 35. Lurbe E, Alvarez V, Liao Y, Tacons J, Cooper R, Cremades B, et al. The impact of obesity  
383 and body fat distribution on ambulatory blood pressure in children and adolescents. *Am*  
384 *J Hypertens*. 1998;11:418-424
- 385 36. Movahed M-R, Bates S, Strootman D, Sattur S. Obesity in adolescence is associated with  
386 left ventricular hypertrophy and hypertension. *Echocardiography*. 2011;28:150-153
- 387 37. Sivanandam S, Sinaiko AR, Jacobs DR, Steffen L, Moran A, Steinberger J. Relation of  
388 increase in adiposity to increase in left ventricular mass from childhood to young  
389 adulthood. *The American Journal of Cardiology*. 2006;98:411-415
- 390 38. Mensah GA, Treiber FA, Kapuku GK, Davis H, Barnes VA, Strong WB. Patterns of body fat  
391 deposition in youth and their relation to left ventricular markers of adverse  
392 cardiovascular prognosis. *The American journal of cardiology*. 1999;84:583-588
- 393 39. Brady TM, Appel LJ, Holmes KW, Fivush B, Miller ER, 3rd. Association between adiposity  
394 and left ventricular mass in children with hypertension. *Journal of clinical hypertension*  
395 *(Greenwich, Conn.)*. 2016;18:625-633
- 396 40. Wang T, Chen L, Yang T, Huang P, Wang L, Zhao L, et al. Congenital heart disease and  
397 risk of cardiovascular disease: A meta-analysis of cohort studies. *J Am Heart Assoc*.  
398 2019;8:e012030
- 399 41. Urbina EM, Gidding SS, Bao W, Pickoff AS, Berdusis K, Berenson GS. Effect of body size,  
400 ponderosity, and blood pressure on left ventricular growth in children and young adults  
401 in the bogalusa heart study. *Circulation*. 1995;91:2400-2406
- 402 42. Burke GL, Bertoni AG, Shea S, Tracy R, Watson KE, Blumenthal RS, et al. The impact of  
403 obesity on cardiovascular disease risk factors and subclinical vascular disease: The multi-  
404 ethnic study of atherosclerosis. *Arch Intern Med*. 2008;168:928-935



- 405 43. Gillett C, Wong A, Wilson DG, Wolf AR, Martin RP, Kenny D. Underrecognition of  
406 elevated blood pressure readings in children after early repair of coarctation of the  
407 aorta. *Pediatric Cardiology*. 2011;32:202-205
- 408 44. Presbitero P, Demarie D, Villani M, Perinetto EA, Riva G, Orzan F, et al. Long term results  
409 (15-30 years) of surgical repair of aortic coarctation. *Br Heart J*. 1987;57:462-467
- 410 45. Zamojska J, Niewiadomska-Jarosik K, Wosiak A, Lipiec P, Stanczyk J. Myocardial  
411 dysfunction measured by tissue doppler echocardiography in children with primary  
412 arterial hypertension. *Kardiol Pol*. 2015;73:194-200
- 413 46. Tran AH, Flynn JT, Becker RC, Daniels SR, Falkner BE, Ferguson M, et al. Subclinical  
414 systolic and diastolic dysfunction is evident in youth with elevated blood pressure.  
415 *Hypertension*. 2020;75:1551-1556
- 416 47. Expert Panel on Integrated Guidelines for Cardiovascular H, Risk Reduction in C,  
417 Adolescents, National Heart L, Blood I. Expert panel on integrated guidelines for  
418 cardiovascular health and risk reduction in children and adolescents: Summary report.  
419 *Pediatrics*. 2011;128 Suppl 5:S213-256
- 420 48. Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, et al. The physical  
421 activity guidelines for americans. *Jama*. 2018;320:2020-2028

422

423

424

425

426

427

428

429

430

431

432

433 **Tables**

434

435 Table 1. Subject characteristics

<b>Characteristic</b>	<b>Overall N = 855<sup>1</sup></b>	<b>Normotensive N = 493<sup>1</sup></b>	<b>Elevated N = 214<sup>1</sup></b>	<b>Stage 1 HTN N = 99<sup>1</sup></b>	<b>Stage 2 HTN N = 49<sup>1</sup></b>
Age (years)	15.48 (1.46)	15.32 (1.47)	15.59 (1.51)	15.91 (1.20)	15.64 (1.37)
Sex					
Female	364 (42.9%)	243 (49.6%)	77 (36.3%)	28 (28.3%)	16 (33.3%)
Male	485 (57.1%)	247 (50.4%)	135 (63.7%)	71 (71.7%)	32 (66.7%)
Race					
White	642 (81.9%)	371 (82.1%)	156 (79.6%)	78 (83.9%)	37 (86.0%)
Black	112 (14.3%)	66 (14.6%)	30 (15.3%)	11 (11.8%)	5 (11.6%)
Other	30 (3.8%)	15 (3.3%)	10 (5.1%)	4 (4.3%)	1 (2.3%)
Height (cm)	165 (13)	163 (13)	168 (13)	170 (12)	169 (11)
Body surface area (m <sup>2</sup> )	1.71 (0.31)	1.62 (0.28)	1.78 (0.28)	1.87 (0.28)	1.96 (0.40)
Weight (kg)	61 (52, 73)	56 (48, 66)	66 (56, 78)	71 (61, 85)	82 (63, 100)
BMI (kg/m <sup>2</sup> )	22.0 (19.2, 25.9)	20.7 (18.5, 24.0)	23.0 (19.9, 26.8)	24.4 (21.2, 29.3)	27.3 (21.9, 32.6)
BMI percentile (%)	68 (37, 92)	60 (29, 84)	77 (48, 93)	86 (59, 96)	95 (78, 98)
BMI category					
Normal	570 (67.1%)	377 (76.9%)	129 (60.8%)	48 (48.5%)	16 (33.3%)
Overweight	127 (15.0%)	59 (12.0%)	37 (17.5%)	22 (22.2%)	9 (18.8%)
Obese	152 (17.9%)	54 (11.0%)	46 (21.7%)	29 (29.3%)	23 (47.9%)
Systolic blood pressure (mm Hg)	117 (108, 126)	110 (104, 114)	124 (122, 126)	133 (131, 136)	146 (142, 152)
Diastolic blood pressure (mm Hg)	64 (59, 70)	62 (58, 68)	66 (60, 72)	67 (60, 76)	72 (64, 80)

<sup>1</sup> Mean (SD); n (%); Medians (IQR)

436 \*HTN, hypertension; BMI, body mass index; SD, standard deviation; IQR, interquartile range

437 Table 2. Echocardiogram Parameters

Characteristic	Overall N = 855 <sup>1</sup>	Normotensive N = 493 <sup>1</sup>	Elevated N = 214 <sup>1</sup>	Stage 1 HTN N = 99 <sup>1</sup>	Stage 2 HTN N = 49 <sup>1</sup>	P value
LVEDD (cm)	4.80 (4.39, 5.20)	4.70 (4.30, 5.10)	4.88 (4.40, 5.30)	5.00 (4.70, 5.38)	4.80 (4.50, 5.20)	<0.05 <sup>2,3</sup>
LVESD (cm)	3.00 (2.70, 3.30)	2.96 (2.60, 3.28)	3.08 (2.79, 3.38)	3.00 (2.77, 3.30)	2.97 (2.70, 3.30)	NS
LVPWd (cm)	0.80 (0.70, 0.90)	0.78 (0.69, 0.85)	0.81 (0.74, 0.90)	0.85 (0.75, 0.94)	0.90 (0.80, 1.00)	<0.05 <sup>2,3,4</sup>
IVSd (cm)	0.80 (0.70, 0.90)	0.80 (0.70, 0.90)	0.90 (0.72, 0.96)	0.90 (0.80, 0.95)	1.00 (0.80, 1.06)	<0.05 <sup>2,3,4</sup>
LVMI Ht <sup>2.7</sup> (g/ht <sup>2.7</sup> )	33 (27, 39)	31 (26, 37)	35 (28, 43)	35 (29, 41)	36 (32, 44)	<0.05 <sup>2,3,4</sup>
LVSF (%)	36.7 (33.3, 41.2)	36.4 (33.0, 40.7)	36.2 (33.3, 41.2)	39.4 (35.9, 42.9)	39.0 (35.1, 43.3)	<0.05 <sup>3</sup>
LVEF (%)	65 (60, 68)	64 (60, 67)	66 (60, 70)	65 (61, 70)	65 (61, 68)	NS

<sup>1</sup> Medians (IQR), <sup>2</sup>Adjusted pairwise p-value <0.05 when NT compared to E-BP, <sup>3</sup>Adjusted pairwise p-value <0.05 when NT compared to HTN-1, <sup>4</sup>Adjusted pairwise p-value <0.05 when NT compared to HTN-2; NS, Non-significant pairwise p-value when NT compared to BP categories

438 \*HTN, hypertension; BMI, body mass index; LVEDD, left ventricular end-diastolic dimension;  
 439 LVESD, left ventricular end-systolic dimension; LVPWd, left ventricular posterior wall thickness  
 440 in diastole; IVSd, interventricular septal thickness in diastole; LVMI Ht<sup>2.7</sup>; left ventricular mass  
 441 indexed to height to the power of 2.7; LVSF, left ventricular shortening fraction; LVEF, left  
 442 ventricular ejection fraction; SD, standard deviation; IQR, interquartile range. Values given as  
 443 medians and IQR.

444 Table 3. Univariable linear regression model for LVMI-ht<sup>2.7</sup>

Characteristic	N	Beta	95% CI <sup>1</sup>	p-value
Age (years)	855	0.84	0.35, 1.3	<b>&lt;0.001</b>
Sex	849			
Female		—	—	
Male		2.7	1.3, 4.2	<b>&lt;0.001</b>
Race	784			
White		—	—	
Black		2.0	-0.08, 4.2	0.060
Other		1.6	-2.2, 5.5	0.4
BMI percentile (%)	849	0.12	0.10, 0.14	<b>&lt;0.001</b>
Systolic blood pressure, 10 mm Hg increase	855	1.4	0.89, 1.9	<b>&lt;0.001</b>

<sup>1</sup> CI = Confidence Interval

445 \*LVMI-ht<sup>2.7</sup>; left ventricular mass indexed to height to the power of 2.7

446

447

448

449

450

451

452 Table 4. Multivariable linear regression model for LVMI-ht<sup>2.7</sup>

Characteristic	Beta	95% CI <sup>1</sup>	p-value
Age (years)	0.77	0.30, 1.2	<b>0.001</b>
Sex			
Female	—	—	
Male	2.7	1.3, 4.1	<b>&lt;0.001</b>
Race			
White	—	—	
Black	1.7	-0.21, 3.7	0.080
Other	1.9	-1.7, 5.5	0.3
BMI percentile (%)	0.11	0.09, 0.14	<b>&lt;0.001</b>
Systolic blood pressure, 10 mm Hg increase	0.26	-0.29, 0.81	0.4

453 \*LVMI-ht<sup>2.7</sup>, left ventricular mass indexed to height to the power of 2.7; BMI, body mass index